Moreover, AFP and ICAM-1 combination application showed higher accuracy in both the diagnosis and prognostic prediction than alone in HCC, and the patients with low-expression of the two indicators were most likely to benefit from ICB therapy. The gene discussed is AFP; the disease is hepatocellular carcinoma.